首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症

市場調查報告書

商品編碼

2126345

預後生物標記市場：策略性洞察與預測（2026-2035）

Prognostic Biomarkers Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月04日 | 出版商:

Knowledge Sourcing Intelligence | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計預後生物標記市場將從 2026 年的 98.2 億美元成長到 2035 年的 229.1 億美元，複合年成長率為 9.9%。

預後生物標記市場正經歷顯著的變革，其驅動力來自精準醫療的模式轉移以及對準確患者風險分層日益成長的需求。這一市場演變的特點在於，人們逐漸認知到客觀的生物學測量對於評估疾病進展、復發、轉移或患者生存期至關重要，且與治療性介入無關。次世代定序、液態生物檢體和人工智慧 (AI) 等先進分子技術的融合，使得跨多個疾病領域的預後評估更加全面和標準化。由於個人化治療的有效性取決於可靠的患者分層，醫療系統正日益將預後生物標記整合到常規臨床工作流程中。製藥公司正在將預後生物標記納入其臨床開發項目，因為篩選出的患者群體能夠提高臨床試驗的效率並加強對臨床終點的評估。隨著對多組體學、血液檢測和人工智慧驅動的解讀工具的大量投資，預後生物標記正逐漸成為精準醫療和以價值為導向的醫療服務模式的關鍵組成部分。

市場促進因素

精準腫瘤學的拓展是預後生物標記市場的主要驅動力。在精準腫瘤學中，在選擇治療性介入前準確評估疾病進展風險至關重要。由於個人化治療的強度取決於可靠的患者分層，醫院和腫瘤中心正日益將預後生物標記整合到常規臨床工作流程中。由於傳統的病理評估對腫瘤異質性的了解有限，人們越來越依賴基因組、轉錄組和蛋白質組生物標記來識別具有不同復發和生存機率的患者。製藥開發商也在臨床試驗中利用這些生物標記，透過選擇具有特定預後特徵的患者群體來提高研究效率並支持標靶治療的開發，從而推動預後生物標記應用的持續成長。液態生物檢體技術的日益普及，透過實現微創臨床監測，進一步加速了市場成長。液態生物檢體技術能夠以微創方式獲取循環生物標記物，從而反映疾病在治療和後續觀察中的進展。由於重複組織切片檢查仍然不切實際或臨床難度較大，醫療專業人員擴大採用基於血液的預後檢測。這種轉變使得持續監測循環腫瘤DNA、循環性腫瘤細胞、外泌體生物標記和遊離核酸成為可能，這些指標可以指示疾病復發或進展。診斷設備製造商正在擴展其液態生物檢體檢測產品組合，同時提高分析靈敏度，使臨床醫生能夠更輕鬆地對患者進行長期監測。多組體學技術正在促進生物標記的發現並提高預後準確性。在生物學異質性疾病中，單一生物標記通常提供的預後資訊有限。整合的分子資料集能夠更全面地闡明疾病的生物學機制，促使研究機構擴大將基因組學、轉錄組學、蛋白質組學、代謝體學和表觀表觀基因結合在一起。定序平台、高通量蛋白質體學和計算分析技術的進步正在加速識別優於傳統生物標記的預後特徵。製藥公司持續與學術機構合作，透過多中心臨床試驗檢驗這些複雜的生物標記組合。生物標記在藥物研發中日益廣泛的應用正在推動商業性擴張和臨床應用。由於患者分層能夠降低研究人群間的差異，製藥公司擴大在臨床開發的各個階段納入預後生物標記。基於生物標記的受試者選擇能夠更好地解讀諸如無惡化生存期和總生存期等終點指標，使申辦方能夠更有效率地產生具有臨床意義的證據。監管機構持續鼓勵在科學合理的情況下進行以生物標記為導向的臨床開發，促使製藥公司在推進治療產品線的同時，拓展其伴隨生物標記策略。

市場限制因素

針對不同患者群體的長期臨床有效性檢驗有限，削弱了醫生的信心，並延緩了新發現的預後生物標記的常規應用。缺乏可靠的檢驗數據導致臨床實施存在不確定性。調查方法、檢體處理和檢查室標準化方面的差異導致生物標記性能的差異，並限制了不同醫療機構之間的可重複性。缺乏統一的方案降低了臨床可靠性。儘管越來越多的臨床證據支持精準醫療，但由於保險報銷方面存在不確定性，一些醫療系統難以採用先進的分子生物標記檢測。保險覆蓋範圍的區域差異給診斷服務提供者帶來不確定性，並限制了患者的就醫途徑。不同司法管轄區的監管複雜性給尋求將新型預後生物標記解決方案商業化的製造商帶來了合規負擔。

透過技術
- 次世代定序（NGS）
- 聚合酵素鏈鎖反應（PCR）
- 免疫組織化學（IHC）
- 原位雜合反應（ISH/FISH）
- 其他技術
依檢體類型
- 組織
- 血
- 尿
- 唾液
- 腦脊髓液（CSF）
- 其他生物體液
按疾病指徵
- 瘤
- 心血管疾病
- 神經病變
- 自體免疫疾病
- 感染疾病
- 代謝性疾病
- 其他疾病適應症
最終用戶
- 醫院
- 臨床實驗室
- 學術研究機構
- 製藥和生物技術公司
- 其他最終用戶

第10章：全球預後生物標記市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球預後生物標記市場：國家分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
韓國
澳洲
巴西
墨西哥
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
QIAGEN NV
Illumina, Inc.
Merck Group
Bio-Rad Laboratories, Inc.
Exact Sciences Corporation
Siemens AG
Myriad Genetics, Inc.
Abbott Laboratories

第14章全球預後生物標記市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009057

The Prognostic Biomarkers Market is expected to grow at a CAGR of 9.9%, from USD 9.82 billion in 2026 to USD 22.91 billion in 2035.

The prognostic biomarkers market is undergoing significant transformation driven by the paradigm shift toward precision medicine and the growing need for accurate patient risk stratification. The market's evolution is characterized by the recognition that objective biological measurements are essential for estimating disease progression, recurrence, metastasis, or patient survival independent of therapeutic intervention. The convergence of advanced molecular technologies, including next-generation sequencing, liquid biopsy, and artificial intelligence, is enabling more comprehensive and standardized prognostic assessment across multiple disease areas. Healthcare systems are increasingly integrating prognostic biomarkers into routine clinical workflows because individualized treatment intensity depends on reliable patient stratification. Pharmaceutical companies are incorporating prognostic biomarkers into clinical development programs because enriched patient populations improve trial efficiency and strengthen clinical endpoint evaluation. The market is witnessing significant investment in multi-omics platforms, blood-based assays, and AI-enabled interpretation tools, positioning prognostic biomarkers as a critical component of precision medicine and value-based healthcare delivery.

Market Drivers

The expansion of precision oncology represents the primary driver for the prognostic biomarkers market. Precision oncology relies on accurate assessment of disease progression risk before selecting therapeutic interventions. Hospitals and oncology centers are increasingly integrating prognostic biomarkers into routine clinical workflows because individualized treatment intensity depends on reliable patient stratification. Conventional pathological evaluation alone provides limited insight into tumor heterogeneity, which increases dependence on genomic, transcriptomic, and proteomic biomarkers capable of identifying patients with varying recurrence and survival probabilities. Pharmaceutical developers also utilize these biomarkers during clinical trials to enrich patient cohorts with defined prognostic characteristics, improving study efficiency and supporting targeted therapy development, resulting in sustained growth in prognostic biomarker utilization. The increasing adoption of liquid biopsy technologies is further accelerating market growth by enabling minimally invasive clinical monitoring. Liquid biopsy technologies provide minimally invasive access to circulating biomarkers that reflect disease evolution throughout treatment and follow-up. Healthcare providers are increasingly adopting blood-based prognostic assays because repeated tissue biopsies often remain impractical or clinically challenging. This shift is supporting continuous monitoring of circulating tumor DNA, circulating tumor cells, exosomal biomarkers, and cell-free nucleic acids that indicate recurrence or disease progression. Diagnostic manufacturers are expanding liquid biopsy assay portfolios while improving analytical sensitivity, allowing clinicians to monitor patients longitudinally with greater convenience. Multi-omics technologies are improving biomarker discovery and prognostic accuracy. Single biomarkers frequently provide limited prognostic information for biologically heterogeneous diseases. Research organizations are increasingly combining genomics, transcriptomics, proteomics, metabolomics, and epigenomics because integrated molecular datasets reveal more comprehensive disease biology. Advances in sequencing platforms, high-throughput proteomics, and computational analytics are accelerating identification of prognostic signatures that outperform conventional biomarkers. Pharmaceutical companies continue collaborating with academic institutions to validate these complex biomarker panels across multicenter clinical studies. Growing biomarker integration in drug development is supporting commercial expansion and clinical adoption. Drug developers increasingly incorporate prognostic biomarkers throughout clinical development because patient stratification reduces variability across study populations. Biomarker-guided enrollment improves interpretation of progression-free survival and overall survival endpoints, allowing sponsors to generate clinically meaningful evidence more efficiently. Regulatory authorities continue encouraging biomarker-supported clinical development where scientifically justified, motivating pharmaceutical companies to expand companion biomarker strategies alongside therapeutic pipelines.

Market Restraints

Limited long-term clinical validation across diverse patient populations restricts physician confidence and delays routine adoption of newly discovered prognostic biomarkers. The lack of robust validation data creates uncertainty for clinical implementation. Differences in analytical methodologies, specimen handling, and laboratory standardization create variability in biomarker performance, limiting reproducibility between healthcare institutions. The lack of harmonized protocols reduces clinical confidence. Reimbursement uncertainty for advanced molecular biomarker assays reduces adoption in several healthcare systems despite increasing clinical evidence supporting precision medicine. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new prognostic biomarker solutions.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of integrated multi-omics platforms and AI-enabled interpretation. Next-generation sequencing enables comprehensive genomic profiling and identification of prognostic signatures. PCR remains important for focused biomarker detection where rapid turnaround is prioritized. IHC continues supporting protein expression assessment for prognostic evaluation. ISH/FISH technologies remain essential for gene amplification and rearrangement detection. Liquid biopsy is expanding for minimally invasive monitoring of circulating biomarkers. The segment analysis reveals that blood represents one of the fastest-growing sample types because minimally invasive collection enables repeated monitoring throughout disease progression and treatment. Liquid biopsy technologies are increasingly detecting circulating tumor DNA, circulating tumor cells, cell-free nucleic acids, and protein biomarkers without requiring repeated tissue biopsies. Oncology constitutes the largest disease indication because cancer prognosis varies considerably despite similar clinical staging. Healthcare providers are increasingly utilizing genomic signatures, gene-expression panels, circulating tumor DNA, and protein biomarkers to estimate recurrence risk, metastatic potential, and long-term survival. Cardiovascular diseases are creating sustained demand as aging populations increase the prevalence of heart failure, coronary artery disease, and acute cardiovascular events. Neurological disorders are generating growing opportunities because neurodegenerative diseases often progress silently before clinical symptoms become irreversible. Pharmaceutical and biotechnology companies represent a strategically significant end-user segment because biomarker-guided clinical development improves trial efficiency and therapeutic differentiation. Clinical diagnostic laboratories and hospitals are expanding testing capabilities. The integration of AI is becoming increasingly important because AI enables analysis of complex molecular datasets that exceed traditional statistical approaches. Clinical laboratories are increasingly integrating machine learning algorithms with genomic and digital pathology platforms because automated pattern recognition improves prognostic model performance.

Competitive and Strategic Outlook

The competitive landscape features established diagnostics and life science companies alongside specialized precision medicine and AI-driven analytics providers. Roche maintains a leading position in precision diagnostics through its integrated pharmaceuticals and diagnostics business, enabling the co-development of biomarkers and targeted therapies, with its sequencing, tissue diagnostics, and companion diagnostic portfolio supporting prognostic biomarker adoption across oncology and personalized medicine. Thermo Fisher Scientific provides comprehensive life science technologies, including NGS, PCR, mass spectrometry, and bioinformatics platforms used in biomarker discovery and clinical validation, with its broad laboratory solutions strengthening translational research and clinical diagnostic workflows. QIAGEN specializes in molecular diagnostics and sample technologies, offering PCR, digital PCR, and NGS workflow solutions for biomarker research and clinical testing, continuing to expand companion diagnostics and precision medicine partnerships with pharmaceutical developers. Illumina is a global leader in NGS technologies that enable comprehensive genomic profiling for prognostic biomarker identification, with its sequencing platforms supporting clinical laboratories, research institutes, and pharmaceutical companies in advancing precision medicine. Merck Group provides life science research tools, reagents, cell biology products, and analytical technologies supporting biomarker discovery and validation. Bio-Rad develops digital PCR systems, life science reagents, and clinical diagnostic products that support highly sensitive biomarker detection and molecular testing. Companies are pursuing product portfolio expansion through innovation in multi-omics platforms, liquid biopsy assays, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for biomarker development alongside targeted therapies. Recent key developments include Massive Bio announcing a partnership with Sequence Me Now to streamline genomic profiling and match cancer patients to appropriate clinical trials. Quanterix highlighted a landmark JAMA study reporting that a combined multi-analyte blood biomarker panel improved prognostic stratification of individuals with subjective cognitive decline versus single-marker approaches. Artera announced De Novo authorization for ArteraAI Prostate, making it the first FDA-authorized AI software to prognosticate long-term outcomes in non-metastatic prostate cancer. OncoAssure announced the U.S. launch of its prognostic OncoAssure Prostate test, which combines genomic and clinical data to assess risk of aggressive disease and recurrence. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The prognostic biomarkers market is positioned for sustained growth driven by the convergence of precision medicine, technological innovation, and expanding healthcare investment. The transition from single-analyte testing toward integrated multi-omics platforms represents a fundamental shift in prognostic assessment. While challenges related to clinical validation, standardization, and reimbursement variability persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with prognostic biomarkers evolving into an essential component of personalized healthcare, supporting risk stratification, treatment optimization, and improved patient outcomes across oncology and beyond.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Prognostic Biomarkers Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Disease Burden & Clinical Significance of Prognostic Biomarkers
3.8 Epidemiology and Disease Prevalence Analysis
3.9 Diagnosed Patient Population Analysis
3.10 Treatment Landscape and Clinical Decision-Making
3.11 Biomarker Development and Validation Landscape

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Biomarker Technologies
6.2 Multi-Omics and Integrated Biomarker Development
6.3 AI and Machine Learning in Prognostic Biomarker Discovery
6.4 Product Innovation
6.5 Clinical Trial Analysis
6.6 Pipeline Analysis
6.7 Companion Diagnostic and Precision Medicine Integration

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Prognostic Biomarkers Market Landscape Analysis

8.1 Analysis by Biomarker Type
8.2 Analysis by Technology Platform
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Disease Indication
8.6 Analysis by Testing Methodology

9. Global Prognostic Biomarkers Market Segment Analysis (2021-2035)

9.1 By Technology
- 9.1.1 Next-Generation Sequencing (NGS)
- 9.1.2 Polymerase Chain Reaction (PCR)
- 9.1.3 Immunohistochemistry (IHC)
- 9.1.4 In Situ Hybridization (ISH/FISH)
- 9.1.5 Other Technologies
9.2 By Sample Type
- 9.2.1 Tissue
- 9.2.2 Blood
- 9.2.3 Urine
- 9.2.4 Saliva
- 9.2.5 Cerebrospinal Fluid (CSF)
- 9.2.6 Other Biofluids
9.3 By Disease Indication
- 9.3.1 Oncology
- 9.3.2 Cardiovascular Diseases
- 9.3.3 Neurological Disorders
- 9.3.4 Autoimmune Diseases
- 9.3.5 Infectious Diseases
- 9.3.6 Metabolic Disorders
- 9.3.7 Other Disease Indications
9.4 By End User
- 9.4.1 Hospitals
- 9.4.2 Clinical Diagnostic Laboratories
- 9.4.3 Academic & Research Institutes
- 9.4.4 Pharmaceutical & Biotechnology Companies
- 9.4.5 Other End Users

10. Global Prognostic Biomarkers Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Prognostic Biomarkers Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Japan
11.9 China
11.10 India
11.11 South Korea
11.12 Australia
11.13 Brazil
11.14 Mexico
11.15 Saudi Arabia

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 F. Hoffmann-La Roche Ltd.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Thermo Fisher Scientific Inc.
13.3 QIAGEN N.V.
13.4 Illumina, Inc.
13.5 Merck Group
13.6 Bio-Rad Laboratories, Inc.
13.7 Exact Sciences Corporation
13.8 Siemens AG
13.9 Myriad Genetics, Inc.
13.10 Abbott Laboratories